MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) had a remarkable revenue and a record gross margin bolstered by its strategic acquisition of VIVO Cannabis Inc. and its inaugural commercial delivery to the U.S. market.
released its financial results for the second quarter ending June 30, 2023. The results have been nothing short of impressive, showcasing a doubling of revenue and a record-breaking margin growth.
MediPharm said its first commercial delivery to the United States marked a significant milestone for the company. This delivery, which was for a large-scale phase two clinical trial, underscores the company’s commitment to expanding its global footprint.
Furthermore, the all-equity business combination has been instrumental in doubling the company’s revenue from the previous year.
Diving deeper into the financials, MediPharm’s Q2 2023 revenue stood at a $9.6 million. This figure represents a staggering 120 per cent increase compared to Q2 2022 and a 64 per cent growth from Q1 2023. Such a leap in revenue can be attributed to the successful integration of VIVO and the company’s strategic market positioning.
The gross profit for Q2 2023 was reported at $800,000, which translates to 8.1 per cent of the total revenue. This is a significant uptick from previous quarters, showcasing the company’s ability to maintain profitability amidst expansion.
When adjusted for specific items, the gross margin was approximately 21 per cent, indicating efficient operations and cost management.
Company stock was flat on Wednesday at $0.075 on the Toronto Stock Exchange.
Read more: Avicanna and Medipharm Labs expand partnership for self-emulsifying cannabinoid capsules
Read more: MediPharm closes sale of Australian facility for $6.3M
The company’s balance sheet remains robust. With $14.7 million in cash reserves, MediPharm is in a strong position to fund its future endeavours. This figure has grown from the previous quarter, highlighting the company’s consistent financial performance. Moreover, the company’s debt is less than $3 million, further solidifying its financial stability.
The successful integration of VIVO has also led to a restructuring and cost-savings program. This initiative is projected to save approximately $7 million annually, aligning with the company’s previously communicated synergy target of $7-$9 million.
“In Q2, we continued to make progress by growing our revenue base, improving gross margins, reducing expenses and reducing cash burn as we drive towards profitability,” MediPharm Labs CFO David Pidduk said.
“We have also demonstrated that we can quickly integrate and drive synergies through acquisitions.”
Greg Hunter, CFO of MediPharm Labs, also weighed in, highlighting the company’s growth in revenue, improved gross margins, and reduced expenses. He further stressed the company’s drive toward achieving sustained profitability.
With these robust financial results and the rapid growth in the medical cannabis sector, MediPharm Labs is poised for further expansion. The company says its expertise in precision-based cannabinoids, coupled with its recent financial achievements, makes it a force to be reckoned with in the industry.
